Markets

Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma

Aug 17, 2026 · 08:03 AM ET· updated 1h ago

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platformGlioblastoma is

Why It Matters

Evaxion is working on a new medicine that uses AI to help fight a really serious brain cancer called glioblastoma. When a company grows the number of treatments it's developing, it shows they're trying to help more people, but new medicines take a long time to test and might not work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

EVAX3.33

-0.01 (-0.30%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.